To the Editor: Leprosy (Hansen disease) is caused by Mycobacterium leprae, an extremely slow-growing, intracellular, acid-fast bacillus with a typical incubation period \( \geq 2–5 \) years, ranging up to 20 years. Anesthetic, thickened skin lesions and granulomatous inflammation in biopsy specimens are typical findings because direct visualization of the organism from biopsy specimens is unreliable (1).

The worldwide prevalence of leprosy is estimated to be \(<181,000\) cases (annual incidence \( \approx 220,000\) new cases in recent years), of which \(96\%\) (173,760) occur in 14 countries (2). In the United States, \(\approx 150\) cases are reported annually, two thirds of which are associated with overseas exposure; the remainder are believed to be domestically acquired (3).

We report a case of multibacillary leprosy in a 44-year-old man, an active member of the US military, residing in southern California, USA, who had a 2-week history of fatigue and large, erythematous plaques on the extremities. He was born in the Philippines and resided there until immigrating to the United States at 23 years of age. He subsequently joined the US military and served as an administrator in clinical and microbiology research laboratories. He resided in California, Maryland, Japan, Egypt, Guam, and Indonesia. He also was deployed to Afghanistan and had vacationed in Laos, Cambodia, and Thailand. Family history was unremarkable. No household or other ill contacts were identified.

Initial evaluation showed a weakly positive antinuclear antibody titer, which prompted consideration of cutaneous lupus. Annular skin lesions subsequently developed on his face, limbs, and trunk (Figure, panel A). His fatigue persisted, and further rheumatologic evaluation did not show any unusual results. Dermatologic evaluation showed madarosis, thickening of the glabella, and 8 large annular plaques. Light touch sensation was impaired, but all lesions were hypersensitive to trauma.

A skin biopsy specimen showed perineural lymphohistiocytic inflammation and nonnecrotizing granulomata (Figure, panel B). Results of acid-fast and Grocott’s methenamine silver (fungal) staining were negative. A presumptive diagnosis of leprosy was made, and he was referred to the Division of Infectious Diseases at Naval Medical Center San Diego for subspecialty management. Dapsone and rifampin were given for multibacillary leprosy. Clofazamine was not available from the manufacturer at time of treatment. After 6 months of therapy, the patient’s lesions were less prominent, and cutaneous sensation had improved. A 2-year treatment course was completed and resulted in total resolution of cutaneous lesions. Residual anesthesia remained only over the right pinna. His course was without complication by either reversal reaction or erythema nodosum leprosum.

Understanding of the transmission of M. leprae has been impeded by difficulty cultivating the organism in vitro. Transmission is believed to occur by prolonged exposure to nasal secretions of patients with high bacillary loads. Infection might also result from exposure to cutaneous lesions or animal reservoirs, such as 9-banded armadillos (3).

Leprosy has been linked to defects in cell-mediated immunity. Milder disease has been associated with human leukocyte antigen HLA-DR3, and more severe disease has
been associated with HLA-DQ/DR variants (4). Although most persons lack susceptibility, high nasal carriage rates in disease-endemic areas and living conditions associated with poverty further increase infection risk for susceptible persons because acquisition is facilitated by malnutrition, overcrowding, and poor sanitation (5).

Leprosy treatment is determined according to disease severity. The Ridley-Jopling system assesses lesion quantity, neurologic involvement, and bacterial load, and the current World Health Organization system simplifies this system to facilitate clinical classification, defining paucibacillary leprosy as ≤5 skin lesions and multibacillary leprosy as ≥6 lesions (6).

Combination drug regimens for 6–24 months are highly effective. Together with efforts of the World Health Organization toward eradication, combination therapy has dramatically reduced the prevalence to current levels from previously stable levels of 10–12 million in the 1960s–1980s (7). Typical regimens include dapsone and rifampin, and clofazimine is available in the United States by investigational new drug application for multibacillary disease.

Patients undergoing treatment must be monitored for immunologic complications, such as cell-mediated reversal reaction (type 1 reaction) or interferon-α–mediated erythema nodosum leprosum (type 2 reaction). Reversal reactions may be especially severe and require urgent immunosuppression to avoid neurologic and vascular complications.

Leprosy is extremely rare in the United States (150 annual cases). Because transmission by prolonged close contact is more common than by casual contact, it is likely that the infection in this patient may have been acquired during childhood in a disease-endemic area, which represents the upper limit of incubation time. However, rare cases have been reported among military members, which makes it difficult to exclude the question of acquisition during military service in disease-endemic areas (8–10). Therefore, in patients with geographically appropriate foreign service or prolonged travel history, leprosy must be considered in the differential diagnosis of progressive skin lesions, particularly when lesional anesthesia is present.

References
1. Britton WJ, Lockwood DN. Leprosy. Lancet. 2004;363:1209–19. http://dx.doi.org/10.1016/S0140-6736(04)15952-7
2. Global leprosy update, 2013; reducing disease burden. Wkly Epidemiol Rec. 2014;89:389–400.
3. Truman RW, Singh P, Sharma R, Basso P, Rougemont J, Paniz-Mondolfi A, et al. Probable zoonotic leprosy in the southern United States. N Engl J Med. 2011;364:1626–33. http://dx.doi.org/10.1056/NEJMoai1010536
4. Blackwell JM, Jamieson SE, Burgner D. HLA and infectious diseases. Clin Microbiol Rev. 2009;22:370–85. http://dx.doi.org/10.1128/CMR.00048-08
5. Lavania M, Turankar RP, Karri S, Chaitanya VS, Sengupta U, Jadhav RS. Cohort study of the seasonal effect on nasal carriage and the presence of Mycobacterium leprae in an endemic area in the general population. Clin Microbiol Infect. 2013;19:970–4. http://dx.doi.org/10.1111/1469-0691.12087
6. Pardillo FE, Fajardo TT, Abalos RM, Scollard D, Gelber RH. Methods for the classification of leprosy for treatment purposes. Clin Infect Dis. 2007;44:1096–9. http://dx.doi.org/10.1086/512809
7. Noordeen SK, Lopez Bravo L, Sundaresan TK. Estimated number of leprosy cases in the world. Bull World Health Organ. 1992;70:7–10.
8. Bailey MS. Tropical skin diseases in British military personnel. J R Army Med Corps. 2013;159:224–8. http://dx.doi.org/10.1136/jramc-2013-000124
9. Chambers JA, Baffi CW, Nash KT. The diagnostic challenge of Hansen’s disease. Mil Med. 2009;174:652–6. http://dx.doi.org/10.7205/MILMED-D-02-9208
10. Brubaker ML, Binford CH, Trautman JR. Occurrence of leprosy in U.S. veterans after service in endemic areas abroad. Public Health Rep. 1969;84:1051–8. http://dx.doi.org/10.2307/4593754

Address for correspondence: Catherine M. Berjohn, Division of Infectious Diseases, Naval Medical Center San Diego, Bldg 1, 2nd Deck, 34800 Bob Wilson Dr, San Diego, CA 92134, USA; email: catherine.berjohn@med.navy.mil

---

**Tickborne Relapsing Fever in Southern Iran, 2011–2013**

**Saied Reza Naddaf, Behnaz Ghazinezhad, Mohammad Mehdi Sedaghat, Hossein Masoumi Asl, Sally Jane Cutler**

Author affiliations: Pasteur Institute of Iran, Tehran, Iran (S.R. Naddaf, B. Ghazinezhad); Tehran University of Sciences, Tehran (M.M. Sedaghat); Ministry of Health and Medical Education, Tehran (H.M. Asl); University of East London, London, United Kingdom (S.J. Cutler)

DOI: http://dx.doi.org/10.3201/eid2106.141715

**To the Editor:** Tickborne relapsing fever (TBRF) is endemic in Iran; >1,400 cases were confirmed in 19 provinces during 1997–2006 (1). In the western, northwestern, and foothill regions of the Alborz Mountains, the Argasid soft tick *Ornithodoros tholozani* is commonplace and accounts for ≈60% of TBRF cases attributed to *Borrelia persica*. However, in central and western Iran, *O. tholozani* and *B. microti*–infected *O. erraticus* ticks coexist (1,2). Two other *Borrelia* species, *B. latuschewii* and *B. baltazardi*, have also been described in northeastern and northwestern Iran (3,4), but no recent human infections with these species have been documented. Cases of TBRF occurring in southern Iran have presumably been caused by *B. microti* because its tick vector, *O. erraticus*, predominates in this region.

Relapsing fever infections in Hormozgan Province in southern Iran are commonly identified during routine checks for malaria. During 2011–2013, blood samples were obtained from 14 febrile patients referred to medical centers in Jask and Rodan in Hormozgan Province.